Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7716774 | 0.94 | TSHR (0.48) | TSHRPPARDACHE | |
| SCHEMBL11524014 | 0.92 | TSHR (0.46) | TSHRPPARDACHE | |
| SCHEMBL13854206 | 0.90 | TSHR (0.45) | TSHRPPARDACHETP53TDP1 | |
| SCHEMBL491513 | 0.87 | TSHR (0.54) | TSHRPPARDACHETP53TDP1 | |
| SCHEMBL16625357 | 0.79 | PPARD (0.46) | TSHRPPARDACHETDP1 | |
| SCHEMBL5017294 | 0.79 | PPARD (0.64) | TSHRPPARDTP53TDP1 | |
| SCHEMBL7268189 | 0.79 | PPARD (0.64) | TSHRPPARDTP53TDP1 | |
| SCHEMBL40352 | 0.79 | TSHR (0.50) | TSHRPPARDTP53TDP1 | |
| SCHEMBL19245610 | 0.78 | PPARD (0.45) | TSHRPPARDACHE | |
| SCHEMBL19398541 | 0.78 | TSHR (0.48) | TSHRPPARDACHETP53TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090123507-A1 | Metal Oxide Nanoparticles Coated With Specific N-Acylaminomethylene Phosphonates | CIBA SPECIALTY CHEMICALS CORP. | 2009-05-14 | — | — | US | disclosed |
| EP-1565461-A2 | ANTIBACTERIAL SUBSTITUTED CYANOMETHYL(ENE)PIPERIDINOPHENYL OXAZOLIDINONES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Patel, Mahesh V. (IN) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004007489-A2 | ANTIBACTERIAL SUBSTITUTED CYANOMETHYL (ENE) PIPERIDINOPHENYL OXAZOLIDINONES, PROCESS OR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WOCKHARDT LIMITED (IN) | 2004-01-22 | — | — | WO | disclosed |
| EP-1254137-A1 | PYRIDO 2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-11-06 | — | — | EP | disclosed |
| US-6423870-B1 | ANTICOAGULANTS; CIRCADIAN RHYTHM DISORDERS; SLEEP DISORDERS | LES LABORATOIRES SERVIER (FR) | 2002-07-23 | — | — | US | disclosed |
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| WO-2001055147-A1 | PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| EP-0315399-B1 | Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same | RHONE POULENC RORER INT (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| US-4299943-A | PRODUCED BY REACTING SILYL DIESTER OF A PENTAVALENT ORGANIC METAL ACID WITH A TETRAVALENT METAL | OCCIDENTAL RESEARCH CORPORATION (US) | 1981-11-10 | — | — | US | disclosed |
| US-4151229-A | Process for the manufacture of aminoalkyl-phosponic acid esters | CIBA-GEIGY CORPORATION (US) | 1979-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090123507-A1 | Metal Oxide Nanoparticles Coated With Specific N-Acylaminomethylene Phosphonates | PHOSPHO1, ACP1, PNN | TSHR 3940/4885PPARD 3000/4885ACHE 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.